113 related articles for article (PubMed ID: 15545308)
1. The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
Cirillo I; Martin NE; Brennan B; Barrett JS
J Clin Pharmacol; 2004 Dec; 44(12):1379-84. PubMed ID: 15545308
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers.
Emmons GT; Argenti R; Martin LL; Martin NE; Jensen BK
J Clin Pharmacol; 2004 Aug; 44(8):901-5. PubMed ID: 15286094
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers.
Martin NE; Collison KR; Martin LL; Tardif S; Wilding I; Wray H; Barrett JS
J Clin Pharmacol; 2003 May; 43(5):529-38. PubMed ID: 12751274
[TBL] [Abstract][Full Text] [Related]
4. Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
Pfister M; Martin NE; Haskell LP; Barrett JS
J Clin Pharmacol; 2004 Jun; 44(6):621-31. PubMed ID: 15145970
[TBL] [Abstract][Full Text] [Related]
5. Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects.
Shah B; Emmons G; Rohatagi S; Martin NE; Jensen BK
Am J Ther; 2003; 10(5):356-62. PubMed ID: 12975720
[TBL] [Abstract][Full Text] [Related]
6. No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
Martin NE; Howell SR; Martin LL; Cirillo I; Barrett JS
J Clin Pharmacol; 2004 Apr; 44(4):379-87. PubMed ID: 15051745
[TBL] [Abstract][Full Text] [Related]
7. Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia.
Chodjania Y; Tharaux PL; Ragueneau I; Dussaule JC; Picker JL; Funck-Brentano C; Jaillon P
Clin Pharmacol Ther; 2002 Jun; 71(6):468-78. PubMed ID: 12087350
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.
Rousso P; Buclin T; Nussberger J; Brunner-Ferber F; Brunner HR; Biollaz J
Eur J Clin Pharmacol; 2000 Jan; 55(10):749-54. PubMed ID: 10663454
[TBL] [Abstract][Full Text] [Related]
9. Site-specific absorption of M100240 and MDL 100,173 in rats evaluated using Sweetana-Grass diffusion chamber technology.
Hwang KK; Jiang L; Ren Y; Martin LL; Martin NE
J Pharmacol Toxicol Methods; 2002; 48(2):97-101. PubMed ID: 14565566
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.
French JF; Flynn GA; Giroux EL; Mehdi S; Anderson B; Beach DC; Koehl JR; Dage RC
J Pharmacol Exp Ther; 1994 Jan; 268(1):180-6. PubMed ID: 8301555
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
12. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.
Hauns B; Hermann R; Hünnemeyer A; Herzog R; Hauschke D; Zech K; Bethke TD
J Clin Pharmacol; 2006 Oct; 46(10):1146-53. PubMed ID: 16988203
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
14. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Kakuda TN; Falcon RW
Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
16. Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers.
Chen YX; Cabana B; Kivel N; Michaelis A
J Clin Pharmacol; 2007 Jul; 47(7):841-9. PubMed ID: 17463218
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
19. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Sunkara G; Sabo R; Wang Y; He YL; Campestrini J; Rosenberg M; Howard D; Dole WP
J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
[TBL] [Abstract][Full Text] [Related]
20. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
